Description
Prednisolone is a derivative of cortisol and a metabolite of prednisone; it exhibits immunosuppressive and anti-inflammatory activities. Prednisolone activates glucocorticoid receptors and is clinically used to treat inflammatory and autoimmune disorders. In mononuclear cells from subjects with multiple sclerosis, prednisolone decreases expression of T-bet, IFNγ, and phosphorylated STAT1, decreasing lymphocyte apoptosis. Additionally, prednisolone delays the progression of Duchenne muscular dystrophy (DMD), altering muscle fiber types in vivo. This form of prednisolone is water soluble.
References
Frisullo G, Nociti V, Iorio R, et al. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol. 2007 Sep;124(3):284-93. PMID: 17627892.
Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J. 2005 May;19(7):834-6. Erratum in: FASEB J. 2005 May;19(7):1 p following 836. Hoffmann, Eric P [corrected to Hoffman, Eric P]. PMID: 15734791.
Davis M, Williams R, Chakraborty J, et al. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol. 1978 Jun;5(6):501-5. PMID: 656293.
